References

The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

1. Moss B. Poxviridae: The viruses and Their Replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, Lippincott Raven, Philadelphia, USA (1996): 2637-2671.

2. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004;4(6):1-17.

3. Fenner F, Wittek R, Dumbell KR. Vaccinia virus: The tool for smallpox eradication. In: The Orthopoxviruses. Fenner F, Wittek R, Dumbell, eds. New York: Academic Press, Inc., 1989:143-170.

4. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Therapy 2002;9:1001-1012.

5. Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus: entry, egress, and evasion. In: Coronaviruses and Arteriviruses. Enjuanes A, ed. New York:Plenum Press, 1998:395-414.

6. Hsaio JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999;73:8750-8761.

7. Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparin sulfate. J Virol 1998;72:1577-1585

8. Salzman NP. The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus. Virology 1960;10:150-152.

9. Payne LG. Adsorption and penetration of enveloped and naked vaccinia virus particles. J Virol 1978;27:19-27.

10. Vanderplasschen A, Hollinshead M, Smith GL. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol 1998;79:877-887.

11. Vanderplasschen A, Smith GL. A novel binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J Virol 1997;71:4032-4041.

12. Hsaio JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999;73:8750-8761.

13. Sodeik B, Cudmore S, Ericsson M, Esteban M, Niles EG, Griffiths G. Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. J Virol 1999;73:8750-8761.

14. Galmiche MC, Rindisbacher L, Wels W, Wittek R, Buchegger F. Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumor cell targeting. J Gen Virol 1997;78:3019-3027.

15. Katz E, Wolffe EJ, Moss B. The ctuoplasmic and transmemvrane domains of the vaccinia virus b5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997;71(4):3178-3187.

Fig. 3. Differential viral recovery. Vaccinia titers recovered from brain and tumor 4 d after injection of virus intraperitoneally in MC38 subcutaneous tumor bearing mice. Data represents median of 5 values. No recoverable titers are seen in brain tissue form the double deleted virus (VVDDEGFP) whereas the tumor has equivalent titers to wild type.

16. Beaud G. Vaccinia virus DNA replication: a short review. Biochimie 1995;77(10):774-779.

17. Tolonen N, Doglio L, Scheich S, Locker JK. Vaccinia virus DNA replication occurs in endoplasmic reticulum enclosed mini nuclei. Mol Biol Cell 2001;12:2031-2046.

18. Sodeik B, Krijnse-Locker J. Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host? Trends Microbiol 2002;10:15-24.

19. Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 1995;84:195-200.

20. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991;252:1662-1667.

21. Carroll, Moss B. Poxviruses as expression vectors. Curr Opin Biotech 1997;8:573-577.

22. Domi A, Moss B. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 2002; 99:12,415-12,420.

23. Yao XD, Evans DH. High frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into lepoporipoxvirus-infected cells. J Virol 2003;77:7281-7290.

24. Yuen L, Moss B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A 1987;84:6417-6421.

25. Buller RML, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988;62:866-874.

26. Faithi Z, Dyster LM, Seto J, Condit RC, Niles EG. Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus. J Gen.Virol 1991;72:2733-2737.

27. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol 1989;210:749-769.

28. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol 1989;210(4):771-784.

29. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 1997;23:1094-1097.

30. Earl PL, Moss B. Expression of Proteins in Mammalian Cells Using Vaccinia Viral Vectors. In: Current Protocols in Molecular Biology. Ausubel FM, Kinston RE, Moore DD, Seidman JG, Smith JA et al., eds. New York: Green/Wiley Interscience, 1998:16.

31. Boyle DB, Coupar BE. A dominant selectable marker for the construction of recombinant poxviruses. Gene 1988;65(1):123-128.

32. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989;63(9):3829-3836.

33. Moss B. Vaccinia Virus. A Tool for Research and Vaccine Development. Science 1991;252:1662-1667.

34. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003;37:251-271.

35. Gurvich EB, Vilesova IS. Vaccinia virus in postvaccinal encephalitis. Acta Virol 1983;27(2):154-159.

36. Enserink M. Public Health. Treating vaccine reactions: two lifelines, but no guarantees. Science 2002;298:2313.

37. Enserink M. Bioterrorism. In search of a kindler, gentler vaccine. Science 2002:296:1594.

38. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-154.

39. Smith GL, Vanderplasschen A, Law M. The formation and function of extra cellular enveloped vaccinia virus. J Gen Virol 2002;83:2915-2931.

40. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prod rug effect of vaccinia mediated tumor regression. Gene Ther 2000;7:1217-1223.

41. Puhlman M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor directed gene therapy: biodistribution of a thymidine kinas deleted mutant. Cancer Gene Ther 2000;7:66-73.

42. Alcami A, Smith GL. The vaccinia virus soluble alpha/beta interferon(IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000;74(23):11,230-11,239.

43. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks and interferon alpha transmembrane signaling. J Biol Chem 1995;270(27):15,974-15,978.

44. Alcami A, Smith GL. The vaccinia virus soluble interferon-gamma receptor is homodimer. J Gen Virol 2002;83:545-549.

45. Seet BT, McFadden G. Viral chemokine-binding proteins. J Leukoc Biol 2002;72(1):24-34.

46. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998;160(2):624-633.

47. Mahalingam S, Karupiah G. Modulation of chemokines by poxvirus infections. Curr Opin Immunol 2000;12(4):409-412.

48. Smith VP, Byant NA, Alcami A. Ectromelia, vaccinia and coxpox viruses encode secreted interleukin-18 binding proteins. J Gen Virol 2000;81:1223-1230.

49. Calderara S, Xiang Y, Moss B. Orthopoxvirus IL-18 binding proteins: affinities and antagonistic activities. Virology 2001;279:22-26.

50. Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A 2002;99:1491-1496.

51. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999;10:127-136.

52. Van Den Broek M, Bachmann MF, Kohler G, et al. IL-4 and IL-10 antagonize IL-12 mediated protection against acute vaccinia virus infection with a limited role of IFN gamma and nitric oxide synthetase 2. J Immunol 2000;164:371-378.

53. Deonarain R, Alcami A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol 2003;84:1962-1972.

54. Gherardi MM, Ramirez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J GenVirol 2003;84:1961-1972.

55. Eder JP, Kantoff PW, Roper K. A phase I trial of recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6:1632-1638.

56. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant non replicating avipox virus to elicit anti-carcinoembroyinic antigen immune responses. J Clin Oncol 2000;18:3964-3973.

57. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmu-nity. Cancer Res 2000;62:6944-6951.

58. Mastrangelo MJ, Maguire HC, Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1998;6:409-422.

59. Mastrangelo MJ, Maguire HC, Jr, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000;465:391-400.

60. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen specific immunotherapy in patients with MUC 1 advanced cancer. J Gene Med 2003;5:690-699.

61. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-8757.

62. Puhlman M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Human Gene Ther 1999;10:649-657.

63. Mullen JT, Tanabe KT. Viral Oncolysis for Malignant Liver Tumors. Annal Surg Oncol 2003;10:596-605.

64. Gnant M, Puhlman MD, Bartlett DL, Alexander HR. Regional versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases. Annal Surg 1999;230: 352-361.

65. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus-mediated p53 gene therapy of bladder cancer in an orthotopic murine model. J Urol 2005;173:604-609.

66. Haghighat P, Timiryasova T, Chen B, Kajioka E, Gridley DS, Fodor I. Antitumor effect of Il-2, p53, and bax gene transfer in C6 glioma cells. Anticancer Res 2000;20:1337-1342.

67. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001 21;19(17-19):2549-2456.

68. Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther 2000;7:663-670.

69. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA can induce prostatic specific immune response in androgen-modulated human prostate cancer. Urology 1999;53:260-266.

70. Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBuglio AF. Human autoantibodies to CEA induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000;6(1):34-41.

71. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human CEA epitopes form patients immunized with recombinant vaccinia-CEA vaccine. J Natl Caner Inst 1995;87:982-990.

Was this article helpful?

0 0
How To Prevent Skin Cancer

How To Prevent Skin Cancer

Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.

Get My Free Ebook


Post a comment